Diabetic Retinopathy Clinical Practice Guidelines: Customized for Iranian Population

Zhale Rajavi1,2, MD; Sare Safi1,2, MS; Mohammad Ali Javadi1, MD
Mohsen Azarmina1, MD; Siyamak Moradian2, MD; Morteza Entezari2, MD
Ramin Nourinia1, MD; Hamid Ahmadieh1, MD
Armin Shirvani2, MD; Saeid Shahraz3, MD, PhD; Alireza Ramezani1,2, MD
Mohammad Hossein Dehghan2, MD; Mohsen Shahsavari5, MD
Masoud Soheilian1,6, MD; Homayoun Nikkhah1,7, MD; Hossein Ziaei1,2, MD
Hasan Behboudi1, MD; Fereydoun Farrahi1, MD; Khalil Ghasemi Falavarjani10, MD
Mohammad Mehdi Parvareh16, MD; Hamid Fesharaki16, MD; Majid Abrishami12, MD
Nasser Shoeibi12, MD; Mansour Rahimi13, MD; Alireza Javadzadeh14, MD
Reza Karkhaneh15, MD; Mohammad Riazi-Esfahani15, MD
Masoud Reza Manaviat16, MD; Alireza Maleki17, MD
Bahareh Kheiri1, MS; Faegheh Golbafian18, MD

1Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2Ophthalmic Epidemiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3Standardization and CPG Development Office, Deputy of Curative Affairs, Ministry of Health and Medical Education, Tehran, Iran
4Tufts Medical Center, Boston, Massachusetts, USA
5Department of Ophthalmology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
6Department of Ophthalmology, Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
7Department of Ophthalmology, Torfeh Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
8Department of Ophthalmology, Gilan University of Medical Sciences, Rasht, Iran
9Department of Ophthalmology, Alzahra Jundishapur University of Medical Sciences, Alzahra, Iran
10Department of Ophthalmology, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
11Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan, Iran
12Department of Ophthalmology, Mashhad University of Medical Sciences, Mashhad, Iran
13Department of Ophthalmology, Shiraz University of Medical Sciences, Shiraz, Iran
14Department of Ophthalmology, Tabriz University of Medical Sciences, Tabriz, Iran
15Department of Ophthalmology, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran
16Department of Ophthalmology, Yazd University of Medical Sciences, Yazd, Iran
17Department of Ophthalmology, Al Zahra Eye Center, Zahedan University of Medical Sciences, Zahedan, Iran
18Victoria Family Medical Centre, UWO, London, ON, Canada

Correspondence to:
Sare Safi, MS. Knowledge Management Unit, Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, No 23, Paidarfarand St., Boostan 9 St., Pasdaran Ave., Tehran 16666, Iran.
E-mail: sare.safi@yahoo.com

Received: 02-08-2016 Accepted: 24-09-2016

Access this article online
Quick Response Code:
Website: www.jovr.org
DOI: 10.4103/2008-322X.194131

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Rajavi Z, Safi S, Javadi MA, Azarmina M, Moradian S, Entezari M, et al. Diabetic retinopathy clinical practice guidelines: Customized for Iranian population. J Ophthalmic Vis Res 2016;11:394-414.
INTRODUCTION

Diabetes mellitus (DM) is a critical public health issue globally and its prevalence is increasing mostly in developing countries.[1-4] The number of diabetics between 20 and 79 years of age is estimated to be 415 million people in the world and is expected to rise to 642 million in 2040.[5] Iran is one of the most populous countries of the Middle East and the prevalence of diabetes in Iran ranges from 7.7% to 14% in the population aged over 20 years.[2,6,7] In addition, it is estimated that Iran would take the second place in diabetes annual growth after Pakistan.[2]

Diabetic retinopathy (DR) is one of the major complications of diabetes and leading cause of visual impairment or blindness.[8-16] Evidence reveals that nearly all type I and 60% of type II diabetic patients develop some degrees of retinopathy 20 years after diagnosis.[17] Given the increasing number of diabetics worldwide, it is expected that the prevalence of DR increases especially in developing countries.[14] Similarly, DR is a major cause of visual impairment and loss in Iran.[10,11,18,19] Based on the current data, 37% and 29.6% of diabetic cases have some degrees of DR in Tehran and Yazd provinces, respectively.[11,19] On the other hand, therapeutic interventions can prevent the development of severe visual impairment caused by DR in up to 90% of cases.[20]

National clinical practice guidelines (CPGs) comprise thorough clinical recommendations based on valid evidence and are adapted considering their safety, efficacy, cost of diagnostic or therapeutic interventions, and the nation’s needs. These guidelines increase the efficacy of interventions and provide equity in access to treatment for all members of the society. Since CPGs focus on a particular problem, for instance one disease, they can help both the physicians and the patients in making an appropriate decision. These instructions can also be effective in guiding health care policy makers at a national scale. Therefore, clinical guidelines increase both accessibility and quality of health care services.[21,22]

Paragraph D, article 32 of the Fifth 5-Year Development Plan of Iran and the Strategic Objective No. 75 of the Iranian Ministry of Health and Medical Education emphasize on the development, adaptation and implementation of clinical practice guidelines, and extension of health care services and development of evidence based health care at a national level.[23,24] Considering the growing prevalence of diabetes and DR in Iran, its impact on public health, costs imposed on the health care system, and in order to establish the objectives of the Fifth 5-Year Development Plan of Iran and the Strategic Objective No. 75 of the Iranian Ministry of Health and Medical Education, DR CPGs were customized for Iranian population under supervision of the Office for Healthcare Standards, Deputy of Curative Affairs, Iran Ministry of Health and Medical Education.

METHODS

The DR CPGs were adapted for Iranian population in the Knowledge Management Unit (KMU), Ophthalmic Research Center, Shahid Beheshti University of Medical
Sciences, Tehran, Iran. The adapting team included the director and the research deputy of the Ophthalmic KMU, five vitreoretinal specialists, a PhD by research candidate (a Master’s of Science degree holder in Optometry), a Master’s of Science degree holder in biostatistics, and the head of the office for healthcare standards, Deputy of Curative Affairs, Iran Ministry of Health and Medical Education.

**Searching and Identifying the Current Clinical Guidelines**

The National Guidelines Clearinghouse (NGC), Guidelines International Network (G-I-N), National Institute for Clinical Excellence (NICE), Scottish Intercollegiate Guidelines Network (SIGN), New Zealand Guidelines Group, National Health and Medical Research Council (NHMRC), Cochrane, Bandolier, CADTH, Trip Database, PubMed (Clinical queries), Google Scholar, SID, Medlib, Magiran were the databases and websites that were explored in order to extract the relevant clinical guidelines.

**Screening the Guidelines**

The extracted guidelines were screened using the AGREE (appraisal of guidelines for research and evaluation) tool. Ultimately, 3 DR guidelines by the Royal College of Ophthalmologists (2013), American Academy of Ophthalmology (Preferred Practice Pattern 2012), and Australian Diabetes Society (2008) were selected as the reference CPGs.

**Methods Used for Customizing Recommendations**

**Evaluating and appraising the reference CPGs’ recommendations**

Initially, 20 questions on DR were designed and the questions’ components (PICO; Patient, Intervention, Comparison, Outcome) were entered in Table 1. Subsequently, the answers to the questions were extracted from the reference CPGs and the responses were recorded in the same table.

In the process of extraction and analysis of the responses, the questions were evaluated once again and broken down into smaller questions if necessary, and all the above-mentioned steps were repeated for each.

**Analyzing the supporting evidence**

The details of each evidence were recorded in Table 2. Tables 3 shows the levels of evidence.

**Evaluating the recommendations in terms of clinical benefits and adaptability**

After completing Tables 1 and 2, the customization team composed the clinical recommendations respecting the clinical benefits including cost, benefits, and side effects and then recorded those in Table 4. Consequently, the recommendations were revised in Table 5 according to three customization criteria: 1- applicability (access to proper equipments, skills at using them, and their affordability for patient), 2- acceptability (patient’s preferences, cultural considerations and patient’s acceptability of the therapeutic protocol), 3- compatibility (similarity between patient’s characteristics/disease type and their interference with studied evidence).

**Consensus**

All recommendations together with complementary instructions and Tables 1, 2, 4 and 5 were sent to the chairs of the retina and vitreous departments at Ahvaz Jundishapur, Gilan, Iran, Isfahan, Mashad, Tabriz, Tehran, Shahid Beheshti, Shahid Sadoughi, Shiraz and Zahedan Universities of Medical Sciences. As the experts in the field of DR, they were asked to score each recommendation in terms of clinical benefits and customizability, and to provide a total score for each recommendation at the end. In addition, they were asked to provide any further evidence that could potentially change the recommendation.

**Analyzing the consensus scores and developing the final recommendations**

Experts scored the recommendations based on the RAM model. The scores were analyzed and the agreement level for each recommendation was identified. The agreed recommendations were considered as the final

| Table 1. Analysis of recommendations |
|--------------------------------------|
| **Question** | **P** | **I (E)** | **C** | **O** | **Type of question guidelines** | **Phrase of recommendation** | **Level of evidence recommendations** | **Inconsistency of technical breakthrough** | **New systematic review** |
| G1           |       |       |     |     | P, patient or population; I, intervention; E, exposure; C, comparison; O, primary outcomes; G1, American Academy of Ophthalmology (2012); G2, Royal College of England (2013); G3, Australian Diabetes Association (2008) | | | | |
Customized DR CPGs for Iranian Population; Rajavi et al

**RESULTS**

**Recommendations for Screening, Risk Factors and Follow-up**

**Screening and examination**

As reported by the screening programs in the US, England, and Australia, the modality of choice to screen for DR is retinal digital imaging with mydriasis which has a sensitivity of 73-96% and specificity of 78-99%. Considering its feasibility, this test is recommended for screening of DR in Iran as well.[29-36] (EL: I)

Considering the few reported side effects of tropicamide eye drop 1% (1 to 6 in 20,000 cases in different studies) and to improve the sensitivity of funduscopiedmyrasis can be used to provide mydriasis for DR screening in diabetic patients except in those with history of glaucoma.[37-44] (EL: II)

**Risk factors**

**Duration of diabetes**

Regardless of the type, those with longer disease duration are at greater risk for development and progression of DR. Therefore:

- Funduscopiedmyrasis is strongly recommended for type II diabetics at their first eye examination.
- It is recommended that type I diabetics undergo funduscopiedmyrasis 3 to 5 years after diagnosis of diabetes.[17,45-54] (EL: II)

If patients are found to have signs of retinopathy, a follow-up plan should be set up based on the severity of the retinopathy.

(EL: Consensus - IV)

**Blood sugar**

Although tight glycemic control does not necessarily prevent the development of DR, it is recommended that diabetic patients control blood glucose and HbA1C levels in order to reduce the risk of DR progression and consequently the need for treatment.[45,55-60] (EL: I)

**Blood pressure**

Target systolic blood pressure of less than 130 mmHg is recommended for diabetic patients to slow down the progression of DR.[61-65] (EL: I)

**Serum lipids**

- Elevated serum lipid levels increase the risk of development and progression of DR. Therefore, control of serum lipids with statins and fibrates is recommended in diabetic patients.[66-81] (EL: I)
- Hyperlipidemia has been identified as a risk factor for exudative diabetic macular edema. Therefore, control of serum lipids is recommended as a preliminary therapeutic measure in diabetic patients.[66-81] (EL: II)
Kidney disorders
- It is recommended that the patients with diabetes and coexisting kidney disease undergo careful retinal examination due to the risk of developing DR (up to 58%).[82]
- It is recommended that the patients with advanced DR undergo thorough renal function evaluation due to the risk of developing kidney disorders (about 15%).[82]

Vitamin D
As vitamin D deficiency can be associated with progression of DR, consultation with a specialist (endocrinologist, gastroenterologist, or nephrologist) is warranted for diabetic patients with vitamin D deficiency and coexisting renal and gastrointestinal problems.[83‑85]

Smoking
Cigarette smoking has been associated with lower incidence of DR, however, considering the higher rate of morbidity and mortality among smokers, smoking cessation is recommended.[64,77,86‑94]

Pregnancy
A two-fold increase in the risk of DR development during pregnancy warrants educating diabetic women planning a pregnancy. In addition, they should be monitored by regular blood glucose checks and retinal examination during and after the course of pregnancy.[95‑102]

A thorough assessment of DR is recommended before planning a pregnancy.[95‑102]

Genetics
It appears that certain genes are involved in the development and progression of DR that could vary by ethnicity and geographical origin.[103‑122]

Therefore, it is recommended that patients with positive family history of DR undergo more frequent eye examinations.

Coexisting eye diseases with diabetes
- Other diabetic eye diseases such as cataract, optic neuropathy, extraocular muscle paralysis, rubeosis iridis, and the delay in corneal epithelium healing should be taken into consideration in patients with DR.[123‑126]
- It is recommended to examine the iris and angle for the presence of neovascularization prior to initialization of mydriatic eye drops.[123‑126]
- Diabetic candidates for keratorefractive surgery should be well informed about the delayed corneal epithelium wound healing prior to surgery.[123‑126]

Referral and follow-up approach in patients with diabetes
It is recommended to examine the patients with R2 level DR (preproliferative) according to the National Screening Committee Severity Classification System or level 43 (moderate NPDR) according to the Early Treatment Diabetic Retinopathy Study (ETDRS) Severity Classification System at 4-month intervals.[37,63,127‑131]

Diabetic patients should be referred to and followed by ophthalmologists according to the following protocol:[37,63,127‑131]
- All type 2 diabetic patients should undergo fundus examination (with pupil dilatation) and visual acuity measurements at the time of diagnosis and at least every 2 years thereafter.
- Patients with signs of nonproliferative DR (NPDR) should be examined annually or every 3-6 months depending on the severity of DR.
- Patients with mild to moderate NPDR should be examined closely for sight threatening retinopathy.

Table 4. Clinical benefits of the recommendations

| Question | Phrase of recommendation | Level of evidence | Costs | Clinical effectiveness of the recommendation | Clinical effectiveness score |
|----------|--------------------------|-------------------|-------|---------------------------------------------|-----------------------------|
|          |                          |                   |       |                                             |                             |

| Side effects | Side benefits | Effect size | Low | Moderate | High |
|--------------|---------------|-------------|-----|----------|------|

P, patient or population; I, intervention; E, exposure; C, comparison; O, primary outcomes; Low: Score 1-3; Moderate: Score 4-6; High: Score 7-10
• High-risk diabetic patients (long diabetes duration, poor blood glucose control, high blood pressure or high serum lipids) should be examined annually even in the absence of DR.
  (EL: I)
• Children with prepubertal onset of diabetes should be assessed for DR when they reach puberty.
  (EL: III)
• Diabetic women who become pregnant should undergo a comprehensive eye examination in the first trimester and be monitored closely throughout pregnancy.
  (EL: I)

**Recommendations for Diagnosis**

**Retinal imaging**

**Indications for fluorescein angiography**

It is recommended that patients with DR undergo fluorescein angiography in the following conditions:[132-135]

- In cases where funduscopic findings cannot justify the visual impairment (to rule out macular ischemia).
  (EL: III)
- To identify leaking lesions and capillary non-perfusion areas that cannot be detected clinically.
  (EL: II)
- To evaluate the macular capillary network
  (EL: I)

**Precautions for fluorescein angiography**

- It is recommended that patients with known history of cardiovascular diseases, allergy, and lung or kidney disorders have appropriate consultation before undergoing fluorescein angiography.
- Fluorescein angiography should be carried out where equipments for resuscitation, atropine and adrenaline are available.[97,136-143]
- In patients with prior hand, axillary or breast lymph node dissection, dye injection in the ipsilateral side is contraindicated.[97,136-143]
  (EL: Consensus - IV)

**Different types of fluorescein angiography**

Wide-field fluorescein angiography is superior in cases with peripheral retinal lesions as it could alter the classification of the DR and therapeutic and follow-up approaches.
  (EL: II)
Availability of wide-field fluorescein angiography can be limited to the major ophthalmology centers.[144,145]
  (EL: Consensus - IV)

**Other imaging modalities**

New imaging modalities for evaluation of DR include optical coherence tomography (OCT), retinal thickness analysis (RTA) techniques, and fundus autofluorescence (FAF).[146-173]

- Due to the particular properties of OCT such as demonstrating different layers of retina, the use of OCT is recommended in the following conditions:
  o To determine the macular thickness in diabetic macular edema (before and after treatment)
  o To detect vitreoretinal traction or any membrane on the macula
- Due to the particular properties of new fluorescein angiography techniques (SLO [Scanning Laser Ophthalmoscopy] Angiography) such as high-speed imaging, high resolution, possibility of digitally storing the images, and integrating the patients’ data from different medical centers, it is suggested these imaging modalities be available in the majority of public and private settings.
  
- FAF can investigate functional changes in retinal pigment epithelium (RPE) without the injection.
  (EL: III)

**Classification of DR and diabetic macular edema**

The most appropriate classification system (severity grading) of DR and diabetic macular edema (DME) could be selected based on the level of health care service offered. Due to the lower complexity, the lower-level health care provider can utilize the International Clinical
Disease Severity Scale and the subspecialty eye care centers can use the ETDRS severity scale to classify the severity of DR and macular edema.\[29-32,127,174-186]\n
**Recommendations for Treatment**

**Laser therapy**

**Indications for panretinal photocoagulation (PRP)**

According to Diabetic Retinopathy Study (DRS), PRP should be performed at the high-risk proliferative DR (PDR) stage. However, early PRP may be considered for severe NPDR and early PDR in the following conditions:\[98,135,187‑214]\n
1. Elderly diabetes type II patients.
2. Prior to cataract surgery.
3. In one‑eyed patients where the vision of the other eye was lost due to PDR.
4. Patients who cannot be regularly examined and followed.
5. Pregnancy.

- If possible, PRP should be delivered on the same day of the diagnosis of high‑risk PDR and if not, within 2 weeks from the time of diagnosis. (EL: I)
- PRP should be postponed until clinically significant macular edema (CSME) is treated. (EL: II)
- Coexisting high-risk PDR and CSME should be treated with combined PRP plus intravitreal antivascular endothelial growth factor (VEGF) injection or macular laser photocoagulation (MPC). (EL: Consensus ‑ IV)
- In cases with fresh vitreous hemorrhage, PRP is usually applied after intravitreal injection of anti‑VEGF when the ocular media is clear. (EL: Consensus ‑ IV)
- In patients with florid type DR, PRP may be applied with shorter intervals (3‑5 days between PRP sessions instead of 1‑4 weeks). (EL: Consensus ‑ IV)
- Patients should be followed every 1‑4 weeks during the course of PRP and every 2‑4 months thereafter until regression of the neovessels and a stable condition is obtained. (ETDRS). (EL: I)
- In patients with shallow anterior chamber who are predisposed to acute glaucoma attack, YAG laser peripheral iridotomy should be performed before PRP. (EL: Consensus ‑ IV)
- In patients who are unable to maintain eye fixation during PRP such as those with nystagmus, retrobulbar anesthesia may be considered in order to avoid unwanted macular burns. (EL: Consensus, IV)
- Patients should be informed about the possible complications of PRP such as visual field restriction and reduced amplitude of accommodation before treatment. (EL: Consensus - IV)

**Indications of macular laser treatment**

Macular laser photocoagulation should be considered in the following conditions:\[135,191,215‑218]\n
- Presence of clinically significant macular edema (CSME) according to ETDRS. (Most recent studies recommend intravitreal injection of anti-VEGF in cases with center involving macular edema and visual acuity of less than 20/30 to 20/40; however, if the macular center is spared and visual acuity is higher than 20/30 to 20/40, macular laser photocoagulation can be applied.) (EL: I)
- Any of the following conditions even in the absence of CSME features:
  - Progression of macular edema towards the central parts of the macula
  - Patients who cannot be followed every 3 months
  - Cataract surgery candidates with leaking macular lesions may receive macular laser treatment preoperatively.
  - Permanent vision loss in the fellow eye due to CSME.
  - In order to prevent aggravation of macular edema, PRP candidates with coexisting DME should receive intravitreal anti-VEGF injection prior to laser treatment. (EL: I, II)

**Follow-up after macular laser photocoagulation**

- According to DRS and ETDRS, patients should be followed at 2‑4 month intervals after macular laser treatment; decision for retreatment will be based upon visual acuity (20/30 or 20/40) and involvement of the central macula thereafter.\[135,215,216\] (EL: I)

**New laser therapy techniques**

New laser treatment techniques can minimize the damage to the internal retinal layers and include the followings:\[219‑231\]

- Minimally invasive subthreshold laser
- Pattern automated scanner laser (PASCAL)

**Recommendation:** Considering the lower risk of retinal damage with minimally invasive subthreshold technique, a limited number of laser machines equipped with these technologies are recommended to be available in ophthalmology centers.\[219‑231\] (EL: IV – Consensus)
Customized DR CPGs for Iranian Population; Rajavi et al

Intravitreal injection

Indications
Intravitreal injection of anti-VEGF drugs is recommended in the following conditions:[166,232-326]

- Diabetic patients with diffuse macular edema and poor prognosis for focal laser treatment
- Patients with PDR or florid PDR and no response to laser therapy
- Patients with neovascularization of iris (NVI) and neovascular glaucoma (NVG)
- For patients with concomitant DR and cataract, consultation with a retinal specialist may be considered prior to cataract surgery whether intravitreal injection should be carried out at the time of cataract surgery (EL: I)

Intravitreal injection before vitrectomy

- Patients with PDR and active neovascularization who have been planned for vitrectomy may receive intravitreal anti-VEGF injection within one week before surgery to minimize intraoperative and early postoperative bleeding.[327] (EL: I)
- Patients with advanced DR and active fibrovascular tissue who are vitrectomy candidates may receive intravitreal anti-VEGF injection within one week before the surgery to minimize the risk of bleeding during and after the surgical procedure.[328-332] (EL: I)
- Extensive fibrovascular tissue increases the risk of traction retinal detachment following intravitreal injection of anti-VEGF drugs; the time interval between the injection and vitrectomy should be not more than 2-3 days in such cases.[328-334] (EL: II)

Intravitreal agents
None of the intravitreal anti-VEGF agents is preferred over the others and the treatment choice depends on the availability and cost.[215,240,244,247,284,302,303,315,316,318,321,332-333] (EL: Consensus - IV)

Complications
Complications of intravitreal injection treatment:
- Specific potential complications:
  - Anti-VEGF drugs: Thromboembolic events, blood pressure elevation, myocardial infarction (MI) and stroke.

  Recommendation: Patients with the past history of MI, stroke, thromboembolism, or uncontrolled hypertension, should receive intravitreal anti-VEGF injection after consultation with a cardiologist.[238,239,307,333,335,336] (EL: I)

Recommendation: Intravitreal triamcinolone injection is not recommended for phakic eyes with the past history of glaucoma.[238-239,307,333-337] (EL: I)
- General complications:
  - Endophthalmitis, retinal detachment, lens damage and cataract, vitreous hemorrhage, subconjunctival hemorrhage and pain.

  Recommendation: Intravitreal injection should be carried out under aseptic conditions to prevent endophthalmitis. In addition, the anatomy of the eye should be kept in mind to minimize the risk of damage to ocular tissues.[238,239,307,333,335,337] (EL: IV)

  Recommendation: Intravitreal anti-VEGF injection is not recommended in eyes with advanced PDR and significant fibrous proliferation due to the risk of traction retinal detachment except in vitrectomy candidates.[238,239,307,333,335-337] (EL: II)

Vitrectomy

Indications
Vitrectomy is recommended for diabetic eyes in the following conditions:[157,338-350]
- Vitreous opacity
  - Severe non-clearing, recurrent vitreous hemorrhage
- Retinal detachment (RD)
  - Tractional RD involving or threatening the macula
  - Combined rhegmatogenous and tractional RD
- Diffuse CSME with taut hyaloid face and no response to previous intravitreal injections and laser photocoagulation
- Active and extensive fibrovascular proliferation (EL: IV)

Considerations
- Early vitrectomy is recommended in the following conditions:
  - Severe vitreous hemorrhage in patients with diabetes type I (EL: I)
  - Patients with very poor vision (5/200) and severe vitreous hemorrhage (EL: I)
  - Active fibrovascular proliferation (EL: II)
  - Severe PDR refractory to PRP (EL: I)

Further recommendation
Studies have shown that while stopping anti-coagulant medications decreases the risk of vitreous hemorrhage during vitrectomy, at the same time it increases mortality. Therefore, decision regarding maintenance or perioperative discontinuation of anticoagulation therapy should be made before vitrectomy by having appropriate consultations about patients’ systemic conditions.[351-353] (EL: II)
Cataract surgery in diabetic patients

Patients should undergo thorough retinal examination prior to the surgery. [261‑263,354‑370] (EL: II)

Coexisting PDR should be treated with PRP preoperatively if media is clear. However, in eyes with poor visualization due to cataract, fundus examination should be performed as soon possible following cataract surgery. [261‑263,354‑370] (EL: I)

Patients with DME should receive intravitreal injection of steroid or anti-VEGF preoperatively to lower the risk of DME aggravation. [261‑263,354‑370] (EL: I)

Patients should undergo more frequent retinal examinations postoperatively due to their increased risk for progression of DR. [261‑263,354‑370] (EL: II)

OCT should be done postoperatively to monitor diabetic macular edema. [261‑263,354‑370] (EL: II)

Diabetic patients who are cataract surgery candidates should be well informed about the risk of DR progression and probable consequent decreased vision and the necessity of frequent eye examination postoperatively. [261‑263,354‑370]

DISCUSSION

Considering the high prevalence of DM and the role of DR as a leading cause of visual impairment and blindness, clinical practice guidelines for DR was adapted for Iranian population at the Knowledge Management Unit, Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran at the request of the Ministry of Health and Medical Education to promote the diagnostic and therapeutic services and enhance community access to evidence-based eye care. [10,11,18,371] Different management aspects of DR including screening, risk factors, follow-up, diagnosis and treatment were taken into account in this guideline.

The retinal experts reached consensus for the majority of the CPGs’ recommendations and approved them as the final recommendations. However, those with no agreement upon were discussed, reviewed and revised, and the final recommendations were composed as follows:

Recommendations for Screening, Risk Factors and Follow-up

Recommendation for vitamin D

This recommendation was primarily described as “Vitamin D level is recommended to be checked in diabetics and treatment is advised for vitamin D deficient patients to decrease the risk of developing DR”. However, vitamin D administration is not completely in the field of ophthalmology and could result in adverse effects in some patients. Therefore, this recommendation was ultimately revised to “As vitamin D deficiency can be associated with progression of DR, consultation with a specialist (endocrinologist or gastroenterologist, or nephrologist) is warranted for diabetic patients with vitamin D deficiency and coexisting renal and gastrointestinal problems.” in order to share the responsibility of correcting Vitamin D with other specialists; hence minimizing the adverse outcomes.

Recommendations for Diagnosis

Recommendation for precautions for fluorescein angiography

Considering the large number of patients in whom fluorescein angiography is recommended, this recommendation was reviewed and after taking patients safety and consultation costs into account was revised from “Relevant consultations are recommended prior to performing fluorescein angiography in patients with history of heart and vascular problems, drug allergy, and lung and kidney diseases” to “It is recommended that patients with known history of cardiovascular diseases, allergy, and lung or kidney disorders have appropriate consultation before undergoing fluorescein angiography”.

Recommendation for different types of fluorescein angiography

This recommendation was primarily described as “Wide-field fluorescein angiography is superior for peripheral retinal lesions and could alter patient’s classification and impact treatment and follow-up plans”. However, with respect to the experts’ opinion, clinical preferences, and costs, this recommendation was reviewed and the indications became clearer and the ultimate recommendation was changed to “Wide-field fluorescein angiography is superior in cases with peripheral retinal lesions as it could alter the classification of the DR and therapeutic and follow-up approaches. Availability of wide-field fluorescein angiography can be limited to the major ophthalmology centers”.

Recommendation for other imaging modalities

With respect to the consensus reached and the viewpoints of the technical committee of the Ministry of Health and Medical Education, the recommendation for retinal imaging underwent major revision and the final version was composed.

The primary recommendation was as follows: “New imaging techniques for retinopathy include Heidelberg retina angiograph (HRA), optical coherence
tomography (OCT), retinal thickness analyzer (RTA) and fundus autofluorescence (FAF).

a. OCT in DR is recommended for the following scenarios:
   1. Macular thickness measurements, follow-up or treatment of macular edema
   2. To diagnose tractional macular thickening.

b. HRA, as an angiographic tool has the following characteristics:
   1. Providing digital images
   2. High speed angiography
   3. High resolution.

c. FAF is employed for evaluating the functional RPE changes without need to inject any dye.

It is recommended to use these imaging tools, for the above-mentioned purposes with exception of RTA that has no clinical application.

However, following experts’ consensus and considering the professional suggestions of the mentioned committee to specify the clinical application of the recommendation, the recommended conditions for using OCT were revised. In addition, specific characteristics of the new fluorescein angiography techniques including high speed, high resolution, and saving images in digital format were described. The application of FAF was also defined more precisely and the final version was composed as follows:

“New imaging modalities for evaluation of DR include new angiographic, retinal thickness analysis (RTA) techniques, optical coherence tomography (OCT) and fundus autofluorescence (FAF).

• Due to the particular properties of OCT such as demonstrating different layers of retina, the use of OCT it is recommended to be used in the following conditions:
  o To determine the macular thickness in diabetic macular edema (before and after treatment)
  o To detect vitreoretinal traction or any membrane on the macula.

• Due to the particular properties of new fluorescein angiography techniques (SLO [Scanning Laser Ophthalmoscopy] Angiography) such as high-speed imaging, high resolution, possibility of digitally storing the images, and integrating the patients’ data from different medical centers, it is suggested that these imaging modalities be available in the majority of public and private settings.

• FAF can investigate functional changes in retinal pigment epithelium (RPE) without the injection.”

Recommendations for Treatment

Recommendations for treatment are the most important part in this clinical guideline, therefore the customization team revised them multiple times based on the experts’ opinions.

Recommendation for indications of macular laser treatment

This recommendation was primarily written as follows:

“Macular Laser treatment is recommended in the following scenarios:

1. Presence of CSME according to ETDRS study
2. One of the following conditions even in the absence of diagnostic criteria for CSME:
   o Macular edema progressing to central macula (leaking upper macular lesions, hard exudate approaching the central macula)
   o In patients incapable of regular follow-up every 3 months
   o Cataract surgery candidates (in patients with cataract who have leaking macular lesions in their fundus, laser treatment of macular edema is recommended before the cataract surgery)
   o Permanent vision loss in the fellow eye as a result of CSME
   o In PRP candidates, laser treatment of macula is recommended prior to or concurrent with PRP to prevent worsening of macular edema.”

This recommendation was revised to emphasize on intravitreal anti-VEGF injections as one of the principal treatments for macular edema as below:

“Macular laser photocoagulation should be considered in the following conditions:

• Presence of clinically significant macular edema (CSME) according to ETDRS.
  (More recent studies recommend intravitreal injection of anti-VEGF in cases with center involving macular edema and visual acuity of less than 20/30 to 20/40; however, if the macular center is spared and visual acuity is higher than 20/30 to 20/40, macular laser photocoagulation can be applied.)

• Any of the following conditions even in the absence of CSME features:
  o Progression of macular edema towards the central parts of the macula
  o Patients who cannot be followed every 3 months
  o Cataract surgery candidates with leaking macular lesions may receive macular laser treatment preoperatively.
  o Permanent vision loss in the fellow eye due to CSME.
  o In order to prevent aggravation of macular edema, PRP candidates with coexisting diabetic macular edema (DME) should receive intravitreal anti-VEGF injection prior to undergoing laser treatment.”

Recommendation for follow-up after macular laser photocoagulation

The primary recommendation of the customization team for follow-up after laser treatment of the macula was:
“After laser treatment for macular edema, follow-up is recommended every 2-4 months until stabilization of the condition. Subsequent laser retreatment will be planned based on visual acuity (better than 20/30) and no involvement of central fovea.” According to the Ministry of Health and Medical Education Technical Committee, the reason of disagreement in the consensus process was re-evaluated. For this purpose and in order to make this recommendation more practical, a determinant VA for retreatment was extracted from two valid references.\textsuperscript{[215,135]} VA of “20/30” was replaced by “20/30 or 20/40” and the final recommendation was composed as:

“According to DRS and ETDRS, patients should be followed at 2-4 months intervals after macular laser treatment; decision for retreatment will be based on visual acuity (better than 20/30 or 20/40) and involvement of the central fovea thereafter.”

**Recommendation for new laser therapy techniques**

Considering the high cost of the instrument equipped with minimal invasive subthreshold technique, the initial recommendation “Considering the availability, lower rate of retinal damage and the higher speed of laser procedure with the retinal laser platform by the minimal invasive subthreshold technique, it is recommended for ophthalmologists to use the above-mentioned retinal laser platform” was replaced by “Considering the lower risk of retinal damage with minimally invasive subthreshold technique, a limited number of laser machines equipped with these technologies are recommended to be available in ophthalmology centers”.

In conclusion, customized diabetic retinopathy clinical practice guidelines for Iranian population was composed by applying the higher grade existing evidence in the literature, the opinions of Iranian medical universities’ faculty members under technical supervision of the Office for Healthcare Standards, Deputy of Curative Affairs, Iran Ministry of Health and Medical Education. Hence, in addition to fulfilling strategic objective No. 75 of this ministry, the provided recommendations can standardize the screening, referral, diagnosis, treatment and follow-up of patients with diabetic retinopathy.

**Acknowledgments**

We express our gratitude to the faculty members of all universities for scoring the recommendations of this clinical practice guideline.

We are grateful to Ms. Soheila Khoshneshin for technical assistants.

**Financial Support and Sponsorship**

Nil.

**Conflicts of Interest**

There are no conflicts of interest.

**REFERENCES**

1. Nanditha A, Ma RC, Ramachandran A, Snehalatha C, Chan JC, Chia KS, et al. Diabetes in Asia and the Pacific: Implications for the global epidemic. *Diabetes Care* 2016;39:472-485.

2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. *Diabetes Res Clin Pract* 2010;87:4-14.

3. Prevention of blindness from diabetes mellitus: report of a WHO consultation in Geneva, Switzerland, 9-11 November 2005. Available from: http://www.who.int/blindness/Prevention%20of%20Blindness%20from%20Diabetes%20Mellitus-with-cover-small.pdf. [Last accessed on 2015 Dec 27].

4. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. *Diabetes Res Clin Pract* 2014;103:137-49.

5. International Diabetes Federation. IDF Diabetes Atlas. 6th ed., 2015. Available from: http://www.diabetesatlas.org/component/attachments/?task=download & id=116. [Last accessed on 2016 Jan 25].

6. Esteghamati A, Gouya MM, Abbasi M, Delavari A, Alikhani S, Alaeddini F, et al. Prevalence of diabetes and impaired fasting glucose in the adult population of Iran: National survey of risk factors for non-communicable diseases of Iran. *Diabetes Care* 2008;31:96-98.

7. Hadaegh F, Bozorgmanesh MR, Ghasemi A, Harati H, Saadat N, Azizi F. High prevalence of undiagnosed diabetes and abnormal glucose tolerance in the Iranian urban population: Tehran Lipid and Glucose Study. *BMC Public Health* 2008;8:176.

8. Jones S, Edwards RT. Diabetic retinopathy screening: A systematic review of the economic evidence. *Diabet Med* 2010;27:249-256.

9. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. *Diabetes Care* 2012;35:556-564.

10. Katibe M, Pakravan M, Yaseri M, Pakbin M, Soleimanzad R. Prevalence and causes of visual impairment and blindness in central Iran; The Yazd Eye Study. *J Ophthalmic Vis Res* 2015;10:279-285.

11. Dehghan MH, Katibe M, Ahmadiheh H, Nourinia R, Yaseri M. Prevalence and risk factors for diabetic retinopathy in the 40 to 80 year-old population in Yazd, Iran: The Yazd Eye Study. *J Diabetes* 2015;7:139-141.

12. Judah G, Vlaev I, Gunn L, King D, King D, Valabhji J, et al. Incentives in Diabetic Eye Assessment by Screening (IDEAS): Study protocol of a three-arm randomized controlled trial using financial incentives to increase screening uptake in London. *BMC Ophthalmol* 2016;16:28.

13. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. *Ophthalmic Epidemiol* 2007;14:179-183.

14. Resnikoff S, Pascolini D, Etya’ale D, Kocur I, Pararajasegaram R, Pokharel GP, et al. Global data on visual impairment in the year 2002. *Bull World Health Organ* 2004;82:844-851.

15. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. *Ophthalmology* 1998;105:998-1003.

16. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. *Lancet* 2010;376:124-136.

17. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. *Arch Ophthalmol* 1984;102:527-532.

18. Hatef E, Fotouhi A, Hashemi H, Mohammad K, Jalali KH. Prevalence of retinal diseases and their pattern in Tehran: The Tehran eye study. *Retina* 2008;28:755-762.

19. Javadi MA, Katibeh M, Rafati N, Dehghan MH, Zayeri F, Yaseri M,
et al. Prevalence of diabetic retinopathy in Tehran province: A population-based study. BMC Ophthalmol 2009;9:12.

20. Diabetic Retinopathy PPP. American Academy of Ophthalmology; 2012. Available from: http://www.aaop.org/guidelines-preferredpracticestandards. [Last accessed on 2014 Feb 14].

21. Clinical Practice Guidelines Office for Healthcare Standards, Deputy of Curative Affairs, Ministry of Health and Medical Education, Tehran, Iran; 2015.

22. Jacobson PD. Transforming clinical practice guidelines into legislative mandates: Proceed with abundant caution. JAMA 2008;299:208-210.

23. Available from: http://www.hbi.nhs.uk/NSize/FullStory/News/Id=1200. [Last accessed on 2013 Sep 18].

24. Fifth Five Year Development Plan of the Islamic Republic of Iran (1390-1394). Available at: http://rc.majlis.ir/fa/law/show/790196. [Last accessed on 2013 Sep 7].

25. Appraisal of Guidelines for Research and Evaluation. Available from: http://www.agreetermtrust/or/. [Last accessed on 2016 Jan 10].

26. The Royal College of Ophthalmologists. Diabetic Retinopathy Guidelines; 2012. Available from: http://www.rcophth.ac.uk. [Last accessed on 2014 Feb 12].

27. The Australian Diabetes Society. Guidelines for the Management of Diabetic Retinopathy; 2008. Available from: http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/di15.pdf. [Last accessed on 2014 Feb 18].

28. New Zealand Guidelines Group. Handbook for the Preparation of Explicit Evidence-Based Clinical Practice Guidelines: New Zealand Guidelines Group; 2001.

29. ENSPDR. English National Screening Programme for Diabetic Retinopathy; 2011. Available from: http://www.ndrs.scot.nhs.uk/. [Last accessed on 2014 Mar 10].

30. SDRSC. Scottish Diabetic Retinopathy Screening Collaborative; 2011. Available from: http://www.ndrs.scot.nhs.uk/. [Last accessed on 2014 Mar 10].

31. DRSSW. Diabetic Retinopathy Screening Service for Wales; 2011. Available from: http://www.wales.nhs.uk/sitesplus/864/page/42582.

32. NIDRSP. Northern Ireland DR Screening Programme Annual Report 2008-2009; 2010.

33. Hutchinson A, McIntosh A, Peters J, O’Keeffe C, Khunti K, Baker R, et al. Effectiveness of screening and monitoring tests for diabetic retinopathy – A systematic review. Diabet Med 2000;17:495-506.

34. National Institute for Clinical Excellence. Diabetic retinopathy – Early Management and Screening. London, UK: National Institute for Clinical Excellence; 2001.

35. Moss SE, Klein R, Kessler SD, Rich AE. Comparison between ophtalmoscopy and fundus photography in determining severity of diabetic retinopathy. Ophthalmology 1985;92:62-67.

36. Javitt JC, Aiello LP, Bassi LJ, Chiang YP, Canner JK. Detecting and treating retinopathy in patients with type I diabetes mellitus. Savings associated with improved implementation of current guidelines. American Academy of Ophthalmology. Ophthalmology 1991;98:1565-1573.

37. Management of Diabetic Retinopathy. Clinical Practice Guidelines. Canberra, Commonwealth Department of Health and Family Services; 1997. p. 1-94.

38. Pandit RJ, Taylor R. Mydriasis and glaucoma: Exploding the myth. A systematic review. Diabet Med 2000;17:695-699.

39. Liew G, Mitchell P, Wang JJ, Wong TY. Fundoscopy: To dilate or not to dilate? BMJ 2006;332:3.

40. Javitt JC, Aiello LP, Chiang Y, Ferris FL, Canner JK, Greenfield S. Preventive eye care in people with diabetes is cost-saving to the federal government. Implications for health-care reform. Diabetes Care 1994;17:909-917.

41. Dasbach EJ, Fryback DG, Newcomb PA, Klein R, Klein BE. Cost-effectiveness of strategies for detecting diabetic retinopathy. Med Care 1991;29:20-39.

42. Jacob J, Stead J, Sykes J, Taylor D, Tooke JE. A report on the use of technician ophthalmoscopy combined with the use of the Canon non-mydriatic camera in screening for diabetic retinopathy in the community. Diabet Med 1995;12:419-425.

43. Wolfs RC, Grobbee DE, Hofman A, de Jong PT. Risk of acute angle-closure glaucoma after diagnostic mydriasis in nonselected subjects: The Rotterdam Study. Invest Ophthalmol Vis Sci 1997;38:2683-2687.

44. Mapstone R, Clark CV. Prevalence of diabetes in glaucoma. Br Med J (Clin Res Ed) 1985;291:93-95.

45. Olsen BS, Sjölie A, Hougaard P, Johannesen J, Borch-Johnsen K, Marinelli K, et al. A 6-year nationwide cohort study of glycaemic control in young people with type 1 diabetes. Risk markers for the development of retinopathy, nephropathy and neuropathy. Danish Study Group of Diabetes in Childhood. J Diabetes Complications 2000;14:295-300.

46. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998;105:1801-1815.

47. Casano RA, Bykhovskaya Y, Johnson DF, Hamon M, Torricelli F, Bigozzi M, et al. Hearing loss due to the mitochondrial A1555G mutation in Italian families. Am J Med Genet 1998;79:388-391.

48. Mitchell P, Moffitt PS, Beaumont P. Prevalence of vision-threatening diabetic retinopathy in Newcastle, Australia. Tohoku J Exp Med 1983;141 Suppl:379-383.

49. Mitchell P. The prevalence of diabetic retinopathy: A study of 1300 diabetics from Newcastle and the Hunter Valley. Aust J Ophthalmol 1980;8:241-246.

50. Mitchell P, Moffitt P. Update and implications from the Newcastle diabetic retinopathy study. Aust N Z J Ophthalmol 1990;18:13-17.

51. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984;102:520-526.

52. Varma R, Torres M, Peña F, Klein R, Azen SP, Los Angeles Latino Eye Study Group. Prevalence of diabetic retinopathy in adult Latinos: The Los Angeles Latino eye study. Ophthalmology 2004;111:1298-1306.

53. Hirai FE, Knudtson MD, Klein BE, Klein C. Clinically significant macular edema and survival in type 1 and type 2 diabetes. Am J Ophthalmol 2008;145:700-706.

54. WestSK, Klein R, Rodriguez J, Muñoz B, Bromán AT, Sanchez R, et al. Diabetes and diabetic retinopathy in a Mexican-American population: Proyecto VER. Diabetes Care 2001;24:1204-1209.

55. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995;44:968-983.

56. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853.

57. Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: A prospective observational study (UKPDS 75). Diabetologia 2006;49:1761-1769.

58. Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM; UK Prospective Diabetes Study Group. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol 2004;122:1631-1640.

59. Klein R, Palta M, Allen C, Shen G, Han DP, D’Alessio DJ. Incidence...
of retinopathy and associated risk factors from time of diagnosis of insulin-dependent diabetes. Arch Ophthalmol 1997;115:351-356.

60. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type 1 diabetes. Lancet 1993;341:1306-1309.

61. Massin P, Erginay A, Mercat-Caudal I, Vol S, Robert N, Reach G, et al. Prevalence of diabetic retinopathy in children and adolescents with type 1 diabetes attending summer camps in France. Diabetes Metab 2007;33:284-289.

62. Gallego PH, Craig ME, Hing S, Donaghue KC. Role of blood pressure in development of early retinopathy in adolescents with type 1 diabetes: Prospective cohort study. BMJ 2008;337:a918.

63. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: A systematic review. JAMA 2007;298:902-916.

64. Stratton IM, Cusick M, Chew EY, Chan CC, Kruth HS, Murphy RP, Ferris FL 3rd. The role of lipids and protein kinase Cs in the pathogenesis of diabetic retinopathy. Diabetes Care 1996;19:1291-1293.

65. Wang PH, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61:1086-1097.

66. ACCORD Study Group; ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233-244.

67. Khee AC, Mitchell P, Sunnmanen PA, O’Day J, Davis TM, Moffitt MS, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial. Lancet 2007;370:1687-1697.

68. Chew EY, Klein ML, Ferris FL 3rd, Remaley NA, Murphy RP, Chantry K, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996;114:1079-1084.

69. Sen K, Misra A, Kumar A, Pandey RM. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract 2002;56:1-11.

70. Gupta A, Gupta V, Thapar S, Bhansali A. Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am J Ophthalmol 2004;137:675-682.

71. Klein R, Sharrett AR, Klein BE, Moss SE, Folsom AR, Wong TY, et al. The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: The atherosclerosis risk in communities study. Ophthalmology 2002;109:1225-1234.

72. Ferris FL 3rd, Chew EY, Hoogwerf BJ. Serum lipids and diabetic retinopathy. Early Treatment Diabetic Retinopathy Study Research Group. Diabetes Care 1996;19:1291-1293.

73. Chew EY. Diabetic retinopathy and lipid abnormalities. Curr Opin Ophthalmol 1997;8:59-62.

74. Su DH, Yeo KT. Diabetic retinopathy and serum lipids. Singapore Med J 2000;41:295-297.

75. Cusick M, Chew EY, Chan CC, Kruth HS, Murphy RP, Ferris FL 3rd. Histopathology and regression of retinal hard exudates in diabetic retinopathy after reduction of elevated serum lipid levels. Ophthalmology 2003;110:2126-2133.

76. Curtis TM, Scholfield CN. The role of lipids and protein kinase Cs in the pathogenesis of diabetic retinopathy. Diabetics Metab Res Rev 2004;20:28-43.

77. Cohen RA, Hennekens CH, Christen WG, Krolewski A, Nathan DM, Peterson MJ, et al. Determinants of retinopathy progression in type 1 diabetes mellitus. Am J Med 1999;107:45-51.

78. El‐Asrar AM, Al‐Rubeaan KA, Al‐Amro SA, Kangave D, Moharram OA. Risk factors for diabetic retinopathy among Saudi diabetics. Int Ophthalmol 1998-1999;22:155-161.

79. Lyons TJ, Jenkins AJ, Zheng D, Lackland DT, McGee D, Garvey WT, et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 2004;45:910-918.

80. Ugurlu N, Yildirim Z, Kilic N, Gürsel E. The importance of serum lipids in exudative diabetic macular edema in type 2 diabetic patients. Ann N Y Acad Sci 2007;1100:213-217.

81. van Leiden HA, Dekker JM, Moll AC, Nijpels G, Heine RJ, Bouter LM, et al. Blood pressure, lipids, and obesity are associated with retinopathy: The Hoorn study. Diabetes Care 2002;25:1320-1325.

82. Penno G, Solini A, Zoppini G, Orsi E, Zerbini G, Trevisan R, et al. Rate and determinants of association between advanced retinopathy and chronic kidney disease in patients with type 2 diabetes: The Renal Insufficiency and Cardiovascular Events (RIACE) Italian multicenter study. Diabetes Care 2012;35:2317-2323.

83. Kaur H, Donaghue KC, Chan AK, Benitez-Aguirre P, Hing S, Lloyd M, et al. Vitamin D deficiency is associated with retinopathy in children and adolescents with type 1 diabetes. Diabetes Care 2011;34:1400-1402.

84. Ahmadieh H, Azar ST, Laknis N, Arabi A. Hypovitaminosis D in patients with type 2 diabetes mellitus: A relation to disease control and complications. ISRN Endocrinol 2013;2013:641098.

85. Aksoy H, Akçay F, Kurtul N, Baykal O, Avci B. Serum 1,25 dihydroxy Vitamin D (1,25(OH)2 D3), 25 hydroxy vitamin D (25(OH) D) and parathormone levels in diabetic retinopathy. Clin Biochem 2000;33:47-51.

86. Donaghue K, Chiarelli F, Trotta D, Allgrove J, Dahl-Jorgensen K. ISPAD clinical practice consensus guideline: Microvacular and macrovascular complications associated with diabetes in children and adolescents. Pediatr Diabetes 2009;19(Suppl 2):195-203.

87. Review of Public Health guidance (PH 10) – Smoking cessation services in primary care, pharmacies, local authorities and workplaces, particularly for manual working groups, pregnant women and hard to reach communities. Available from: https://www.nice.org.uk/guidance/ph 10/documents/ smoking-cessation-services-in-primary-care-pharmacies-local-authorities-and-workplaces-particularly-for-manual-working-groups-pregnant-women-and-hard-to-reach-communities-revi-ew-proposal-consultation2. [Last accessed on 2013 Feb 18].

88. Moss SE, Klein R, Klein BE. Association of cigarette smoking with diabetic retinopathy. Diabetes Care 1991;14:119-126.

89. Karamanos B, Porta M, Songini M, Metelko Z, Kerenyi Z, Tamas G, et al. Different risk factors of microangiopathy in patients with type I diabetes mellitus of short versus long duration. The EURODIAB IDDM Complications Study. Diabetologia 2000;43:348-355.

90. Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X. Cost-effectiveness of interventions to prevent and control diabetes mellitus: A systematic review. Diabetes Care 2010;33:1872-1894.

91. Moss SE, Klein R, Klein BE. Cigarette smoking and ten-year progression of diabetic retinopathy. Ophthalmology 1996;103:1438-1442.

92. Martin TL, Selby JV, Zhang D. Physician and patient prevention practices in NIDDM in a large urban managed-care organization. Diabetes Care 1995;18:1124-1132.

93. Telmer S, Christiansen JS, Andersen AR, Nerup J, Deckert T. Smoking habits and prevalence of clinical diabetic microangiopathy in insulin-dependent diabetics. Acta Med Scand 1984;215:63-68.

94. Klein R, Klein BE, Davis MD. Is cigarette smoking associated with diabetic retinopathy? Am J Epidemiol 1983;118:228-238.

95. Klein BE, Moss SE, Klein R. Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care 1990;13:34-40.

96. Hemachandra A, Ellis D, Lloyd CE, Orchard TJ. The influence of pregnancy on IDDM complications. Diabetes Care 1995;18:950-954.
97. Sunness JS. The pregnant woman’s eye. Surv Ophthalmol 1988;32:219-238.

98. Four risk factors for severe visual loss in diabetic retinopathy. The third report from the Diabetic Retinopathy Study. The Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1979;97:654-655.

99. Chan WC, Lim LT, Quinn MJ, Knox FA, McCance D, Best RM. Management and outcome of sight-threatening diabetic retinopathy in pregnancy. Eye 2004;18:826-832.

100. Rahman W, Rahman FZ, Yassin S, Al-Suleiman SA, Rahman J. Progression of retinopathy during pregnancy in type 1 diabetes mellitus. Clin Experiment Ophthalmol 2007;35:231-236.

101. Chen LK, Buchan AM, Hwang SJ, Hinkle J. Cataract surgery after acute stroke: Maybe more than a coincidence. Stroke 2006;37:766-767.

102. Diabetes Control and Complications Trial Research Group. C(‑106) T polymorphism of the aldose reductase gene and risk of severe diabetic retinopathy. Diabetic Medicine 1998;15:637-642.

103. Ramadan W, Rahman FZ, Yassin S, Al-Suleiman SA, Rahman J. Progression of retinopathy during pregnancy in type 1 diabetes mellitus. Clin Experiment Ophthalmol 2007;35:231-236.

104. Warpeha KM, Chakravarthy U. Molecular genetics of diabetic retinopathy in type II diabetic Asian Indians. J Hum Genet 2005;50:267-275.

105. Zintzaras E, Chatzoulis DZ, Karabatsas CH, Stefanidis I. The relationship between C677T methylenetetrahydrofolate reductase gene polymorphism and retinopathy in type 2 diabetes. A meta-analysis. J Hum Genet 2005;50:267-275.

106. Rietveld I, Ikram MK, Vingerling JR, Hofman A, Pols HA, Lamberts SW, et al. An igf-I gene polymorphism modifies the risk of diabetic retinopathy. Diabetes 2006;55:2387-2391.

107. Looker HC, Nelson RG, Chew EY, Mills JL, Metzger BE, Remaley NA, Jovanovic-Peterson L, et al. Proposed international clinical diabetic retinopathy lesion scales. Arch Ophthalmol 2007;125:1354-1361.

108. Quigley HA. Can diabetes be good for glaucoma? Why can’t we believe our own eyes (or data)? Arch Ophthalmol 2009;127:227-229.

109. Wilkinson CP, Ferris FL, Li X, Horton J, Coupland SE, Davis MD, et al. Proposed international clinical diabetic retinopathy lesion scales. Arch Ophthalmol 2007;125:1354-1361.

110. Davis MD, Fisher MR, Gangnon RE, Barton F, Aiello LM, Chew EY, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Invest Ophthalmol Vis Sci 1998;39:233-252.

111. Thomas RK, Melton NR. Pupillary dilation: A view from the trenches. J Am Optom Assoc 1993;64:612.

112. Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmologa 2003;110:1677-1682.

113. Ginsburg LH, Aiello LM. Diabetic retinopathy: Classification, progression and management. Focal Points (AOA). Vol. XI. American Academy of Ophthalmology; 1993. p. 1-14.

114. Thomas RK, Melton NR. Pupillary dilation: A view from the trenches. J Am Optom Assoc 1993;64:612.

115. American Diabetes Association. Diabetic retinopathy. Diabetes Care 2000;23(Suppl 1):S73-6.

116. Errera FI, Canani LH, Silva ME, Yeh E, Takahashi W, Santos KG, et al. Functional vascular endothelial growth factor-634C>C SNP is associated with proliferative diabetic retinopathy: A case-control study in a Brazilian population of European ancestry. Diabetes Care 2007;30:275-279.

117. Suganthalashkini B, Anand R, Kim R, Mahalakshmi R, Karthikprakash S, Narperumalsamy P, et al. Association of VEGF and eNOS gene polymorphisms in type 2 diabetes retinopathy. Mol Vis 2006;12:336-341.

118. Rema M, Saravanan G, Deepa R, Mohan V. Familial clustering of diabetic retinopathy in South Indian type 2 diabetic patients. Diabet Med 2002;19:910-916.

119. Haffner SM. Epidemiology of type 2 diabetes: Risk factors. Diabetes Care 1995;18:631-637.

120. Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes Care 2000;23:1084-1091.

121. Nikzamir A, Rashidi A, Esteghamati A, Nakhjavan M, Golmohammadi T, Khalilzadeh O. The relationship between ACE gene insertion/deletion polymorphism and diabetic retinopathy in Iranian patients with type 2 diabetes. Ophthalmic Genet 2010;31:108-113.

122. Feghhi M, Nikzamir A, Esteghamati A, Mahmoudi T, Yekaninejad MS. Relationship of vascular endothelial growth factor (VEGF) +405 G/C polymorphism and proliferative retinopathy in patients with type 2 diabetes. Transl Res 2011;158:85-91.

123. Jeganathan VS, Wang JJ, Wong TY. Ocular associations of diabetes other than diabetic retinopathy. Diabetes Care 2008;31:1905-1912.

124. Tan GS, Wong TY, Fong CW, Aung T, Singapore Malay Eye Study. Diabetes, metabolic abnormalities, and glaucoma. Arch Ophthalmol 2009;127:1354-1361.

125. Xu L, Xie XW, Wang YX, Jonas JB. Ocular and systemic factors associated with diabetes mellitus in the adult population in rural and urban China. The Beijing Eye Study. Eye (Lond) 2009;23:676-682.

126. Davis MD, Fisher MR, Gangnon RE, Barton F, Aiello LM, Chew EY, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Invest Ophthalmol Vis Sci 1998;39:233-252.

127. Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmologa 2003;110:1677-1682.

128. Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmologa 2003;110:1677-1682.

129. Ginsburg LH, Aiello LM. Diabetic retinopathy: Classification, progression and management. Focal Points (AOA). Vol. XI. American Academy of Ophthalmology; 1993. p. 1-14.

130. Thomas RK, Melton NR. Pupillary dilation: A view from the trenches. J Am Optom Assoc 1993;64:612.

131. American Diabetes Association. Diabetic retinopathy. Diabetes Care 2000;23(Suppl 1):S73-6.

132. American Academy of Ophthalmology. Preferred Practice Pattern: Diabetic Retinopathy. San Francisco (CA): American Academy of Ophthalmology; 2003.

133. Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmologa 1991;98(Suppl 5):807-822.
135. Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no 19. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1995;113:1144-1155.

136. Bloome MA. Fluorescein angiography: Risks. Vision Res 1980;20:1083-1097.

137. Pacaurariu RL. Low incidence of side effects following intravenous fluorescein angiography. Ann Ophthalmol 1982;14:32-36.

138. Yannuzzi LA, Rohrer KT, Tindel LJ, Sobel RS, Costanza MA, Shields W, et al. Fluorescein angiography complication survey. Ophthalmology 1986;93:611-617.

139. Karhunen U, Raita C, Kala R. Adverse reactions to fluorescein angiography. Acta Ophthalmol (Copenh) 1986;64:282-286.

140. Kwiterovich KA, Maguire MG, Murphy RP, Schachat AP, Bressler NM, Bressler SB, et al. Frequency of adverse systemic reactions after fluorescein angiography. Results of a prospective study. Ophthalmology 1991;98:1139-1142.

141. Weaver DT, Herman DC. A contraindication to injection of intravenous fluorescein. Am J Ophthalmol 1990;109:490-491.

142. Brown RE Jr, Sabates R, Drew SJ. Metoclopramide as prophylaxis for nausea and vomiting induced by fluorescein. Arch Ophthalmol 1987;105:658-659.

143. Fluorescein and Indocyanine Green Angiography Guidelines. The Royal Australian and New Zealand College of Ophthalmologists. Australia: The Royal Australian and New Zealand College of Ophthalmologists; 2007. p. 1-6.

144. Kong M, Lee MY, Ham DI. Ultrawide-field fluorescein angiography for evaluation of diabetic retinopathy. Korean J Ophthalmol 2012;26:428-431.

145. Wessel MM, Aaker GD, Parlitis G, Cho M, D’Amico DJ, Kiss S. Ultra-wide-field angiography improves the detection and classification of diabetic retinopathy. Retina 2012;32:785-791.

146. Virgili G, Menchini F, Casazza G, Hogg R, Das RR, Wang X, et al. Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy. Cochrane Database Syst Rev 2015;1:CD008081.

147. Virgili G, Menchini F, Dimastrogiovanni AF, Rapizzi E, Menchini U, Bandello F, et al. Optical coherence tomography versus stereoscopic fundus photography or biomicroscopy for diagnosing diabetic macular edema: A systematic review. Invest Ophthalmol Vis Sci 2007;48:4963-4973.

148. McDonald HR, Williams GA, Scott IU, Haller JA, Maguire AM, Marcus DM; American Academy of Ophthalmology; Ophthalmic Technology Assessment Committee Retina Panel. Laser scanning imaging for macular disease: A report by the American Academy of Ophthalmology. Ophthalmology 2007;114:1221-1228.

149. Panzotto C, Gusson E, Parolini B, Mercanti A. Role of OCT in the diagnosis and follow up of diabetic macular edema. Semin Ophthalmol 2003;18:74-81.

150. Ozdek SC, Erding MA, Gürelık G, Aydin B, Bahçeçi U, Hasanreisoglu B. Optical coherence tomographic assessment of diabetic macular edema: Comparison with fluorescein angiographic and clinical findings. Ophthalmologica 2005;219:86-92.

151. Massin P, Girach A, Erginay A, Gaudric A. Optical coherence tomography: A key to the future management of patients with diabetic macular oedema. Acta Ophthalmol Scand 2006;84:466-474.

152. Browning DJ, McGwen MD, Bowen RM Jr, O’Marah TL. Comparison of the clinical diagnosis of diabetic macular edema with diagnosis by optical coherence tomography. Ophthalmology 2004;111:712-715.

153. Kang SW, Park CY, Ham DI. The correlation between fluorescein angiographic and optical coherence tomographic features in clinically significant diabetic macular edema. Am J Ophthalmol 2004;137:313-322.

154. Jaffe GJ, Caprioli J. Optical coherence tomography to detect and manage retinal disease and glaucoma. Am J Ophthalmol 2004;137:156-169.

155. Gaucher D, Tadayoni R, Erginay A, Haouchine B, Gaudric A, Massin P. Optical coherence tomography assessment of the vitreo-retinal relationship in diabetic macular edema. Am J Ophthalmol 2005;139:807-813.

156. Sánchez-Tocino H, Alvarez-Vidal A, Maldonado MJ, Moreno-Montañés J, García-Layana A. Retinal thickness study with optical coherence tomography in patients with diabetes. Invest Ophthalmol Vis Sci 2002;43:1588-1594.

157. Kaiser PK, Rieman CD, Sears JE, Lewis H. Macular traction detachment and diabetic macular edema associated with posterior hyaloid traction. Am J Ophthalmol 2001;131:44-49.

158. Strom C, Sander B, Larsen N, Larsen M, Lund-Andersen H. Diabetic macular edema assessed with optical coherence tomography and stereo fundus photography. Invest Ophthalmol Vis Sci 2002;43:241-245.

159. Muscat S, Parks S, Kemp E, Keating D. Repeatability and reproducibility of macular thickness measurements with the Humphrey OCT system. Invest Ophthalmol Vis Sci 2002;43:490-495.

160. Massin P, Vicaut E, Haouchine B, Erginay A, Paques M, Gaudric A. Reproducibility of retinal mapping using optical coherence tomography. Arch Ophthalmol 2001;119:1135-1142.

161. Hee MR, Puliafito CA, Duker JS, Reichel E, Coker JG, Wilkins JR, et al. Topography of diabetic macular edema with optical coherence tomography. Ophthalmology 1998;105:360-370.

162. Otani T, Kishi S, Maruyama Y. Patterns of diabetic macular edema with optical coherence tomography. Am J Ophthalmol 1999;127:688-693.

163. Soliman W, Sander B, Hasler PW, Larsen M. Correlation between intraretinal changes in diabetic macular oedema seen in fluorescein angiography and optical coherence tomography. Acta Ophthalmol 2008;86:34-39.

164. Otani T, Kishi S. Correlation between optical coherence tomography and fluorescein angiography findings in diabetic macular edema. Ophthalmology 2007;114:104-107.

165. Alkuraya H, Kangave D, Abu El-Asrar AM. The correlation between optical coherence tomographic features and severity of retinopathy, macular thickness and visual acuity in diabetic macular edema. Int Ophthalmol 2005;26:93-99.

166. Moreira RO, Trujillo FR, Meirelles RM, Ellinger VC, Zagury L. Use of optical coherence tomography (OCT) and indirect ophthalmoscopy in the diagnosis of diabetic edema in diabetic patients. Int Ophthalmol 2001;24:331-336.

167. Polito A, Shah SM, Haller JA, Zimmmer-Galler I, Zeimer R, Campochiaro PA, et al. Comparison between retinal thickness analyser and optical coherence tomography for assessment of foveal thickness in eyes with macular disease. Am J Ophthalmol 2002;134:240-251.

168. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109:920-927.

169. Hassenstein A, Meyer CH. Clinical use and research applications of Heidelberg retinal angiography and spectral-domain optical coherence tomography – A review. Clin Experiment Ophthalmol 2009;37:130-143.
248. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang CE, Massin P, Schlingemann RO, et al. The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. *Ophthalmology* 2011;118:615-625.

249. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. *Ophthalmology* 2010;117:1064-1077.e35.

250. Goyal S, Lavalley M, Subramanian ML. Meta-analysis and review on the effect of bevacizumab in diabetic macular edema. *Graefes Arch Clin Exp Ophthalmol* 2011;249:15-27.

251. Yilmaz T, Cordero-Coma M, Gallagher MJ, Teasley LA. Systematic review of intravitreal bevacizumab injection for treatment of primary diabetic macular oedema. *Acta Ophthalmol* 2011;89:709-717.

252. Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Macondray LA, Iles AJ, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: Report 2. *Ophthalmology* 2012;119:1078-1086.e2.

253. Arevalo JF, Sanchez JW, Wu L, Maia M, Alessandrini AA, Bressler NM, et al. Primary intravitreal bevacizumab for diffuse diabetic macular edema: The Pan-American Collaborative Retina Study Group at 24 months. *Ophthalmology* 2009;116:1488-1497, 1497.e1.

254. Lam DS, Lai TY, Lee VY, Chan CK, Liu DT, Mohamed S, et al. Intravitreal bevacizumab with or without triamcinolone acetonide for refractory diabetic macular edema: a placebo-controlled, randomized clinical trial. *Graefes Arch Clin Exp Ophthalmol* 2008;246:483-489.

255. Soheilian M, Ramezani A, Obudi A, Bijanzadeh B, Yaseri M, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone acetonide versus macular photoacoagulation in diabetic macular edema. *Ophthalmology* 2009;116:1142-1150.

256. Solaiman KA, Diab MM, Abo-Elenin M. Intravitreal bevacizumab and/or macular photoacoagulation as a primary treatment for diffuse diabetic macular edema. *Retina* 2010;30:1638-1645.

257. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. *Br J Ophthalmol* 2008;92:667-668.

258. Do DV, Nguyen QT, Shah SM, Browning DJ, Haller JA, Chu K, et al. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema. *Br J Ophthalmol* 2009;93:144-149.

259. Do DV, Nguyen QT, Boyer D, Schmidt-Erfurth U, Brown DM, Vitti R, et al. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. *Ophthalmology* 2012;119:1658-1665.

260. Lanzagorta-Aresti A, Palacios-Pozo E, Menezo Rozaen JL, Navea-Tejerina A. Prevention of vision loss after cataract surgery: Prospective randomized study. *JAMA* 2011;305:709-717.

261. Akinci A, Muftuoglu O, Altinsoy A, Ozkilic E. Phacoemulsification with intravitreal bevacizumab and triamcinolone acetonide injection in diabetic patients with clinically significant macular edema and cataract. *Retina* 2011;31:755-758.

262. Fard MA, Yazdanei Abyane A, Malili M. Prophylactic intravitreal bevacizumab for diabetic macular edema (thickening) after cataract surgery: Prospective randomized study. *Eur J Ophthalmol* 2011;21:276-281.

263. Ishibashi T, Miki K, Sorgente N, Patterson R, Ryan SJ. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. *Arch Ophthalmol* 1985;103:708-711.

264. Danis RP, Bingaman DP, Yang Y, Ladd B. Inhibition of preretal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. *Ophthalmology* 1996;103:2099-2104.

265. Ciulla TA, Criswell MH, Danis RP, Hill TE. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. *Arch Ophthalmol* 2001;119:399-404.

266. Wang YS, Friedrichs U, Eichler W, Hoffmann S, Wiedemann P. Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells. *Graefes Arch Clin Exp Ophthalmol* 2002;240:42-48.

267. Jonas JB, Hayler JK, Sööker A, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. *Am J Ophthalmol* 2001;131:468-471.

268. Nauck M, Karakulaklis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. *Eur J Pharmacol* 1998;341:309-315.

269. Brooks HL Jr., Caballero S Jr., Newell CK, Steinmetz RL, Watson D, Segal MS, et al. Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. *Arch Ophthalmol* 2004;122:1801-1817.

270. Jonas JB, Kreissig I, Sööker A, Degernring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. *Arch Ophthalmol* 2003;121:57-61.

271. Jonas JB, Sööker A. Intravitreal injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. *Am J Ophthalmol* 2001;132:425-427.

272. Jonas JB. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases. *Acta Ophthalmol Scand* 2005;83:645-663.

273. Jonas JB, Degernring RF, Kamppeet BA. Outcome of eyes undergoing trabeculectomy after intravitreal injections of triamcinolone acetonide. *J Glaucoma* 2004;13:261.

274. Kuhn F, Barker D. Intravitreal injection of triamcinolone acetonide for diabetic macular edema. *Arch Ophthalmol* 2004;122:1082-1083.

275. Savage H, Roh M. Safety and efficacy of intravitreal triamcinolone. *Arch Ophthalmol* 2004;122:1083.

276. Patelli F, Fasolino G, Radice P, Russo S, Zumbo G, DI Tizio FM, et al. Time course of changes in retinal thickness and visual acuity after intravitreal triamcinolone acetonide for diffuse diabetic macular edema with and without previous macular laser treatment. *Retina* 2005;25:840-845.

277. Larsson J, Zhu M, Sutter F, Gillies MC. Relation between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone. *Am J Ophthalmol* 2005;139:802-806.

278. Massin P, Audren F, Haouchine B, Erginay A, Bergmann JF, Benosman R, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: Preliminary results of a prospective controlled trial. *Ophthalmology* 2004;111:218-224.

279. Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone compared with macular laser grid photoacoagulation for the treatment of cystoid macular edema. *Am J Ophthalmol* 2004;140:695-702.

280. Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: Three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. *Ophthalmology* 2004;111:2044-2049.

281. Audren F, Lecler-Mollet A, Erginay A, Haouchine B, Benosman R, Bergmann JF, et al. Intravitreal triamcinolone acetonide for diffuse...
diabetic macular edema: Phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol 2006;142:794-799.

283. Jonas JB, Kamppeter BA, Harder B, Vosserbeumer U, Sauder G, Spandau UH. Intravitreal triamcinolone acetonide for diabetic macular edema: A prospective, randomized study. J Ocul Pharmacol Ther 2006;22:200-207.

284. Audren F, Erginay A, Haouchine B, Benosman R, Conrath J, Bergmann JF, et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial. Acta Ophthalmol Scand 2006;84:624-630.

285. Lam DS, Chan CK, Mohamed S, Lai TY, Li KK, Li PS, et al. A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema. Br J Ophthalmol 2007;91:199-203.

286. Kang SW, Sa HS, Cho HY, Kim JI. Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Arch Ophthalmol 2006;124:653-658.

287. Park DW. Intravitreal triamcinolone and endophthalmitis. Am J Ophthalmol 2003;136:918-919.

288. Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL, Chaudhry NA. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 2003;121:1279-1282.

289. Jonas JB, Kreissig I, Spandau UH, Harder B. Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. Am J Ophthalmol 2006;141:579-580.

290. Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA. Intracocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005;112:593-598.

291. Konstantopoulos A, Williams CP, Newsom RS, Luff AJ. Ocular morbidity associated with intravitreal triamcinolone acetonide. Eye (Lond) 2007;21:317-320.

292. Lang Y, Leibu R, Shoham N, Miller B, Perlman I. Evaluation of intravitreal kenalog toxicity in humans. Ophthalmology 2007;114:724-731.

293. Bandello F, Polito A, Pognuz DR, Monaco P, Dimastrogiovanni A, Paissios J. Triamcinolone as adjunctive treatment to laser panretinal photoocoagulation for proliferative diabetic retinopathy. Arch Ophthalmol 2006;124:643-650.

294. Spandau UH, Derse M, Schmitz-Valckenberg P, Papoulis C. Jonas JB. Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema. Br J Ophthalmol 2005;89:999-1003.

295. Jonas JB, Degenring RF, Kamppeter BA, Kreissig I, Akkoyun I. Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema. Am J Ophthalmol 2004;138:158-160.

296. Rodriguez-Coleman H, Yuan P, Kim H, Gravlin L, Srivastava S, Csaky KG, et al. Intravitreal injection of triamcinolone for diffuse macular edema. Arch Ophthalmol 2004;122:1085-1116.

297. Negi AK, Vernon SA, Lim CS, Owen-Armstrong K. Intravitreal triamcinolone improves vision in eyes with chronic diabetic macular oedema refractory to laser photocoagulation. Eye (Lond) 2005;19:747-751.

298. Gibran SK, Cullinane A, Jungkim S, Cleary PE. Intravitreal triamcinolone for diffuse diabetic macular oedema. Eye 2006;20:720-724.

299. Jonas JB, Spandau UH, Kamppeter BA, Vosserbeumer U, Harder B, Sauder G. Repeated intravitreal high-dosage injections of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology 2006;113:800-804.

300. Kim H, Csaky KG, Gravlin L, Yuan P, Lutz RJ, Bungay PM, et al. Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration. Retina 2006;26:523-530.

301. Pearson P, Levy B, Comstock T. Fluocinolone Acetonide Implant Study Group. Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 3-year results of a multi-centre clinical trial. Invest Ophthalmol Vis Sci 2006;47:5442 [E-abstract 5442].

302. Kuppermann BD, Blumenkrantz MS, Haller JA, Williams GA, Weinberg DV, Chou C, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007;125:309-317.

303. Verma LK, Vivek MB, Kumar A, Tewari HK, Venkatesh P. A prospective controlled trial to evaluate the adjunctive role of posterior subtenon triamcinolone in the treatment of diffuse diabetic macular edema. J Ocul Pharmacol Ther 2004;20:277-284.

304. Bakri SJ, Kaiser PK. Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema. Am J Ophthalmol 2005;139:290-294.

305. Cardillo JA, Melo LA Jr., Costa RA, Skaf M, Belfort R Jr., Souza-Filho AA, et al. Comparison of intravitreal versus posterior sub-Tenon’s capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology 2005;112:1597-1563.

306. Bonini-Filho MA, Jorge R, Barbosa JC, Calucci D, Cardillo JA, Costa RA. Intravitreal injection versus sub-Tenon’s infusion of triamcinolone acetonide for refractory diabetic macular edema: A randomized clinical trial. Invest Ophthalmol Vis Sci 2005;46:3845-3849.

307. Caldwell RB, Bartoli M, Behzadian MA, El-Remessy AE, Al-Shabrawey M, Platt DH, et al. Vascular endothelial growth factor and diabetic retinopathy: Role of oxidative stress. Curr Drug Targets 2005;6:511-524.

308. Zhang SX, Ma JX. Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy. Prog Retin Eye Res 2007;26:1-37.

309. Ng EW, Shima DT, Caliss P, Cunningham ET Jr., Gruer DR, Adams AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006;5:123-132.

310. Gragoudas ES, Adams AP, Cunningham ET Jr, Feinsod M, Gruer DR, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.

311. Adams AP, Altaweel M, Bressler NM, Cunningham ET Jr., Davis MD, Goldbaum M, et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006;113:23-28.

312. Churchill AJ, Carter JG, Lovell HC, Ramsden C, Turner SJ, Yeung A, et al. VEGF polymorphisms are associated with neovascular age-related macular degeneration. Hum Mol Genet 2006;15:2955-2961.

313. Brown DM, Kaiser PK, Michels M, Soubrae G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.

314. Chun DW, Heier J, Topping M, Duker JS, Bankert JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 2006;113:1706-1712.

315. Spaida RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006;26:275-278.

316. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695.e1-15.

317. Mason JO 3rd, Nixon PA, White MF. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2006;142:685-688.

318. Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2006;142:155-158.

319. Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F,
Customized DR CPGs for Iranian Population; Rajavi et al

Bartz-Schmidt KU; Tuebingen Bevacizumab Study Group. Intracamer al bevacizumab for iris rubescens. Am J Ophthalmol 2006;142:158-160.

Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:352-354.

Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;26:999-1005.

Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JC, Wu L, Maia M, et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: Results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 2007;114:743-750.

Yanyali A, Aytag B, Horozoglu F, Nohutcu AF. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol 2007;144:124-126.

Isaacs TW, Barry C. Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin). Clin Experiment Ophthalmol 2006;34:802-803.

Bakri SJ, Donaldson MJ, Link TP. Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab. Eye (Lond) 2006;20:1474-1475.

Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114:1860-1867.

Ahmadieh H, Shoebi N, Entezari M, Monshizadeh R. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: A randomized clinical trial. Ophthalmology 2009;116:1943-1948.

Zhao LQ, Zhu H, Zhao PQ, Hu YQ. A systematic review and meta-analysis of clinical outcomes of vitreous with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy. Br J Ophthalmol 2011;95:1216-1222.

Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S, Williams G. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol 2008;246:837-842.

Yeoh J, Williams C, Allen P, Buttery R, Chiu D, Clark B, et al. Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: A prospective case series. Clin Experiment Ophthalmol 2008;36:449-454.

Oshima Y, Shima C, Wakahayashi T, Kusaka S, Shiraga F, Ohi M, et al. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology 2009;116:927-938.

Zhang ZH, Liu HY, Hernandez-Da Mota SE, Romano MR, Falavarjani KG, Ahmadieh H, et al. Vitreous with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: A meta-analysis of randomized controlled trials. Am J Ophthalmol 2013;156:106-115.e2.

Moradian S, Ahmadieh H, Maliihi M, Soheilian M, Dehghan MH, Azarmina M. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2014;262:1699-1705.

Hernández-Da Mota SE, Núñez-Solorio SM. Experience with intravitreal bevacizumab as a preoperative adjunct in 23-G vitrectomy for advanced proliferative diabetic retinopathy. Eur J Ophthalmol 2010;20:1047-1052.

Gillies MC, Suter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: Two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006;113:1533-1538.

Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: A review of literature. Eye 2013;27:787-794.

POLICY STATEMENT – Intravitreal Injections – American Academy of Ophthalmology-Board of Directors; November, 2008.

Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. The Diabetic Retinopathy Vitrectomy Study Research Group. Arch Ophthalmol 1985;103:1644-1652.

Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial – Diabetic Retinopathy Vitrectomy Study report 3. The Diabetic Retinopathy Vitrectomy Study Research Group. Ophthalmology 1988;95:1307-1320.

Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Clinical application of results of a randomized trial – Diabetic Retinopathy Vitrectomy Study report 4. The Diabetic Retinopathy Vitrectomy Study Research Group. Ophthalmology 1988;95:1321-1334.

Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5. Arch Ophthalmol 1990;108:958-964.

Okamoto F, Okamoto Y, Fukuda S, Hiraoka T, Oshika T. Vision-related quality of life and visual function following vitrectomy for proliferative diabetic retinopathy. Am J Ophthalmol 2008;145:1031-1036.

Massin P, Duguid G, Erginay A, Haouchine B, Gaudric A. Optical coherence tomography for evaluating diabetic macular edema before and after vitrectomy. Am J Ophthalmol 2003;135:169-177.

Ottani T, Kishi S. A controlled study of vitrectomy for diabetic macular edema. Am J Ophthalmol 2002;134:214-219.

Yamamoto T, Hitani K, Tsukahara I, Yamamoto S, Kawasumi R, Yamashita H, et al. Early postoperative retinal thickness changes and complications after vitrectomy for diabetic macular edema. Am J Ophthalmol 2003;135:14-19.

Smiddy WE, Flynn HW Jr. Vitrectomy in the management of diabetic retinopathy. Surv Ophthalmol 1999;43:491-507.

Pendergast SD, Hassan TS, Williams GA, Cox MS, Margherio RR, Ferrone FJ, et al. Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. Am J Ophthalmol 2000;130:178-186.

Ho T, Smiddy WE, Flynn HW Jr. Vitrectomy in the management of diabetic eye disease. Surv Ophthalmol 1992;37:190-202.

‘Esperance FA Jr. The role of vitrectomy in the diabetic patient. J Diabet Complications 1987;1:120-121.

Kieselbach G. Vitrectomy in florid proliferative diabetic retinopathy. Ophthalmologica 1989;199:141-145.

Fabinyi DC, O’Neill EC, Connell PP, Clark JB. Vitreous cavity haemorrhage post-vitrectomy for diabetic eye disease: The effect of perioperative anticoagulation and antiplatelet agents. Clin Experiment Ophthalmol 2011;39:878-884.

Mason JO 3rd, Gupta SR, Compton CJ, Frederick PA, Neimkin MG, Hill ML, et al. Comparison of hemorrhagic complications of warfarin and clopidogrel bisulfate in 25-gauge vitrectomy versus a control group. Ophthalmology 2011;118:543-547.

Brown JS, Mahmoud TH. Anticoagulation and clinically significant postoperative vitreous hemorrhage in diabetic vitrectomy. Retina 2011;31:1983-1987.

Greenberg PB, Tseng VL, Wu WC, Liu J, Jiang L, Chen CK, et al. Prevalence and predictors of ocular complications associated with cataract surgery in United States veterans. Ophthalmology 2011;118:507-514.

Hong T, Mitchell P, de Loryn T, Rchotchyna E, Cugati S, Wang JJ. Development and progression of diabetic retinopathy 12 months
after phacoemulsification cataract surgery. *Ophthalmology* 2009;116:1510-1514.

356. Squirrell D, Bhola R, Bush J, Winder S, Talbot JF. A prospective, case controlled study of the natural history of diabetic retinopathy and maculopathy after uncomplicated phacoemulsification cataract surgery in patients with type 2 diabetes. *Br J Ophthalmol* 2002;86:565-571.

357. Mittra RA, Borriollo JL, Dev S, Mieler WF, Koenig SB. Retinopathy progression and visual outcomes after phacoemulsification in patients with diabetes mellitus. *Arch Ophthalmol* 2001;119:912-917.

358. Chung J, Kim MY, Kim HS, Yoo JS, Lee YC. Effect of cataract surgery on the progression of diabetic retinopathy. *J Cataract Refract Surg* 2002;28:626-630.

359. Kim SJ, Equi R, Bressler NM. Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography. *Ophthalmology* 2007;114:881-889.

360. Aiello LM, Wand M, Liang G. Neovascular glaucoma and vitreous hemorrhage following cataract surgery in patients with diabetes mellitus. *Ophthalmology* 1983;90:814-820.

361. Poliner LS, Christianson DJ, Escoffery RF, Kolker AE, Gordon ME. Neovascular glaucoma after intracapsular and extracapsular cataract extraction in diabetic patients. *Am J Ophthalmol* 1985;100:637-643.

362. Tsopelas N, Kokolakis N, Droutsas D, Theodossiadis G. Extracapsular cataract extraction in diabetic eyes. The role of YAG laser capsulotomy. *Doc Ophthalmol* 1995;91:17-24.

363. Dowler JG, Hykin PG, Lightman SL, Hamilton AM. Visual acuity following extracapsular cataract extraction in diabetes: A meta-analysis. *Eye* 1995;9(Pt 3):313-317.

364. Dowler JG, Hykin PG, Hamilton AM. Phacoemulsification versus extracapsular cataract extraction in patients with diabetes. *Ophthalmology* 2000;107:457-462.

365. Schatz H, Atienza D, McDonald HR, Johnson RN. Severe diabetic retinopathy after cataract surgery. *Am J Ophthalmol* 1994;117:314-321.

366. Liu Y, Luo L, He M, Liu X. Disorders of the blood-aqueous barrier after phacoemulsification in diabetic patients. *Eye (Lond)* 2004;18:900-904.

367. Patel JJ, Hykin PG, Cree IA. Diabetic cataract removal: Postoperative progression of maculopathy – Growth factor and clinical analysis. *Br J Ophthalmol* 2006;90:789-793.

368. Henriksson M, Heijl A, Janzon L. Diabetic retinopathy before and after cataract surgery. *Br J Ophthalmol* 1996;80:821-826.

369. Romero-Aroca P, Fernández-Ballart J, Almena-Garcia M, Méndez-Marín I, Salvat-Serra M, Buil-Calvo JA. Nonproliferative diabetic retinopathy and macular edema progression after phacoemulsification: Prospective study. *J Cataract Refract Surg* 2006;32:1438-1444.

370. Chew EY, Benson WE, Remaley NA, Lindley AA, Burton TC, Csaky K, et al. Results after lens extraction in patients with diabetic retinopathy: Early treatment diabetic retinopathy study report number 25. *Arch Ophthalmol* 1999;117:1600-1606.

371. Rajavi Z, Katibeh M, Ziaei H, Fardesmaeilpour N, Sehat M, Ahmadieh H, et al. Rapid assessment of avoidable blindness in Iran. *Ophthalmology* 2011;118:1812-1818.